Here are five factors influencing the company’s momentum, according to Seeking Alpha:
1. The demand for hip and knee implants continues to increase. In the US, hip and knee implants account for 85 percent of all reconstruction and replacement surgeries.
2. The number of patients undergoing hip and knee replacements is anticipated to increase. A study projects the number of hip replacements will increase 174 percent through 2030.
3. Additionally, the number of knee replacement procedures is projected to increase 673 percent.
4. Between hip and knee replacements, the combined total joint replacement market is estimated to top $35 billion by 2022.
5. Since Stryker’s release of its 2017 fourth quarter financial report, the company has experienced a 6 percent drop in share values. In comparison, the S&P 500 has experienced a 4.3 percent decline, opening the opportunity for investors.
More articles on devices and implants:
OrthAlign passes clinical milestone with 75k joint arthroplasty cases performed — 4 insights
Integra LifeSciences signs lease for new site, bringing 200 jobs to Mansfield: 4 things to know
Life Spine launches new website to improve clinical outcomes: 4 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
